- Login
- Manage Portfolio
- Post a StockTalk
- Write an Instablog
- Get Daily Email Alert
-
Seeking Alpha
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: | |
Articles on ViroPharma Inc. (VPHM)
by latest | most commented
-
Contrarian Stock Screen: Biggest Losers in 2009
-
Smaller Pharma Wins the 'Most Valuable' Race
-
FDA Calendar Updates: ABT, AFFY, AZN, LLY, MELA, PFE, SOMX, VPHM
-
ViroPharma: FDA Issues Complete Response Letter for Cinryze
-
Friday Options Recap
-
Buying ViroPharma Ahead of June 3rd FDA Decision
-
Wall Street Breakfast: Must-Know News
-
Top 10 Dividend, P/S and P/B Ratio Stocks
-
Does More Cash and Less Debt Equal Stock Market Gains?
-
Q1 2009 Biotech Roundup: The Good, the Bad and the Ugly
-
Monday's Options Recap
-
Wall Street Breakfast: Must-Know News
-
Viropharma: Failed Bet on Orphan Drug
-
Viropharma's Antiviral Bombs: Here We Go Again
-
9 Possible Pharma Deals for 2009
-
2009: Positive Outlook for Biotech
-
2008 Stock Market: 51 Rays of Light
-
New Index of Health Product Innovators
-
Weekly FDA Calendar Update
-
Analysts Even More Bullish on ViroPharma
-
Top Ten Magic Formula Stocks with Strong Relative Strength
-
Health Innovator's Index: Does R&D Lead to Higher Stock Prices?
-
Biotech Update: Arena Pharmaceuticals, Acusphere, Cephalon, ViroPharma, Auxilium
-
Cinryze Approved: A Significant Catalyst for Viropharma, Lev Pharmaceuticals
-
Viropharma, Lev Pharmaceuticals: An Attractive Biotech Pair
-
Biotech Names With Big Potential
-
Watch for More Coming Biotech Acquisitions
-
ViroPharma: Lev Acquisition Appraisal
-
Thursday Options Outlook: LEH, MER, XLF, SWY, VPHM, NUE, CIEN, MAR, CTSH
-
American Campus Communities Issuing Secondary; Ulticom Mulling Sale
-
Is ViroPharma a Buy Despite Seemingly Weak Fundamentals?
-
Maribavir Should Guide Viropharma Higher
-
ViroPharma Incorporated: More FDA Incompetence
-
Forecast for ViroPharma's Pipeline: Mostly Shiny
-
ViroPharma Incorporated: Value in a Pharmaceutical
-
Stocks with the Smallest PEG Ratios
-
Biotech In Review: Dyax Jumps On Positive Data
-
ViroPharma: Still Impressive
-
Biotech Stocks Day-in-Review: IPOs Heat Up
-
Investors Infected With Vertex Fever Should Seek Healthier Stocks -- Barron's
-
Analyst Upgrades & Downgrades for Tuesday, August 1, 2006